Key points from article :
Longevity nutrition company L-Nutra raises $47m in Series D fundraising.
L-Nutra develops fasting mimicking technology that nourishes the body while keeping cells in a fasting mode, providing health benefits and enhancing cellular rejuvenation.
L-Nutra has conducted over 30 clinical trials and secured 200 worldwide patents, demonstrating the scientific rigor and efficacy of its technology.
Company's two pipelines, L-Nutra's ProLon and L-Nutra Health, focus on enhancing healthy aging and treating age-related diseases through nutrition as medicine.
L-Nutra CEO Dr Joseph Antoun says the investment reinforces trust in the company's science and mission to increase longevity and healthspan globally.
